Context Therapeutics annual stock-based compensation
2020
2021
2022
2023
2024
2025
Context Therapeutics Stock-Based Compensation Growth & History (CNTX)
Context Therapeutics's stock-based compensation was $1.3M for fiscal 2025.
View full Context Therapeutics company overviewContext Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.3M | $489,213 | +58.11% |
| 2024 | 2024-12-31 | $841,867 | −$234,998 | −21.82% |
| 2023 | 2023-12-31 | $1.1M | $100,425 | +10.28% |
| 2022 | 2022-12-31 | $976,440 | $465,361 | +91.05% |
| 2021 | 2021-12-31 | $511,079 | $291,834 | +133.11% |
| 2020 | 2020-12-31 | $219,245 | — | — |
Context Therapeutics quarterly stock-based compensation
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $528,102 | $138,988 | +35.72% |
| Q1 2026 | 2026-03-31 | $409,220 | $115,503 | +39.32% |
| Q4 2025 | 2025-12-31 | $325,168 | $93,347 | +40.27% |
| Q3 2025 | 2025-09-30 | $323,081 | $110,079 | +51.68% |
| Q2 2025 | 2025-06-30 | $389,114 | $232,077 | +147.78% |
| Q1 2025 | 2025-03-31 | $293,717 | $53,710 | +22.38% |
| Q4 2024 | 2024-12-31 | $231,821 | −$24,230 | −9.46% |
| Q3 2024 | 2024-09-30 | $213,002 | −$41,947 | −16.45% |
| Q2 2024 | 2024-06-30 | $157,037 | −$126,066 | −44.53% |
| Q1 2024 | 2024-03-31 | $240,007 | −$42,755 | −15.12% |
| Q4 2023 | 2023-12-31 | $256,051 | $12,414 | +5.10% |
| Q3 2023 | 2023-09-30 | $254,949 | −$21,572 | −7.80% |
| Q2 2023 | 2023-06-30 | $283,103 | $41,779 | +17.31% |
| Q1 2023 | 2023-03-31 | $282,762 | $67,804 | +31.54% |
| Q4 2022 | 2022-12-31 | $243,637 | $39,257 | +19.21% |
| Q3 2022 | 2022-09-30 | $276,521 | $114,698 | +70.88% |
| Q2 2022 | 2022-06-30 | $241,324 | $121,961 | +102.18% |
| Q1 2022 | 2022-03-31 | $214,958 | $189,445 | +742.54% |
| Q4 2021 | 2021-12-31 | $204,380 | — | — |
| Q3 2021 | 2021-09-30 | $161,823 | — | — |
| Q2 2021 | 2021-06-30 | $119,363 | — | — |
| Q1 2021 | 2021-03-31 | $25,513 | — | — |
Context Therapeutics stock-based compensation trends
Over the last five fiscal years, Context Therapeutics's stock-based compensation increased from $219,245 to $1.3M, a change of $1.1M. The latest reported quarter, Q2 2026, shows $528,102.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Context Therapeutics source filings ↗